CardioExchange Archive

April 16th, 2015

Cangrelor Finally Gets Nod From FDA Advisory Panel

Larry Husten, PHD

On Wednesday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-2-1 to recommend approval of cangrelor during PCI to reduce the risk of periprocedural thrombotic events such as MI, stent thrombosis, and ischemia driven revascularization. The news follows a decade of efforts to develop the drug — a potent, fast-acting, and reversible  antiplatelet agent. After the failure of two […]

---

February 13th, 2014

FDA Advisory Panel Recommends Against Approval of Cangrelor

Larry Husten, PHD

The FDA’s Cardiovascular and Renal Drugs Advisory Committee today recommended against the approval of cangrelor, the investigational new antiplatelet drug from the Medicines Company. In a 7-2 vote, the panel first rejected an indication for the reduction of thrombotic cardiovascular events including stent thrombosis in patients undergoing PCI. The panel also voted unanimously to reject a second indication, for the […]

---

February 10th, 2014

FDA Reviewers Deliver Split Opinion on Cangrelor

Larry Husten, PHD

FDA reviewers presented two dramatically different views of The Medicines Company’s investigational new drug cangrelor. One reviewer says the drug should not be approved without a new trial and even states that the CHAMPION trials “were conducted unethically” and provide sufficient reason to “refuse approval…on that fact alone.”  But two other reviewers recommend approval. On Wednesday the FDA’s Cardiovascular and […]

---

December 16th, 2013

Selections from Richard Lehman’s Literature Review: December 16th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include several trials of genotyping to guide starting doses of vitamin K antagonists, statins for primary prevention of CVD, and more.

---

April 8th, 2013

Selections from Richard Lehman’s Literature Review: April 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include an article on open science through data sharing, primary prevention of CVD with a Mediterranean diet, atherosclerosis found in mummies, and more.

---

March 10th, 2013

ACC.13: Is Cangrelor an Antiplatelet CHAMPION?

Deepak L. Bhatt, MD, MPH, Richard A. Lange, MD, MBA and L. David Hillis, MD

Deepak Bhatt sheds light on findings from the CHAMPION PHOENIX trial and their implications for clinical practice.

---

March 10th, 2013

Cangrelor During PCI May Reduce Ischemic Events

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet […]

---

January 8th, 2013

Early Results: Antiplatelet Drug Cangrelor Superior to Clopidogrel in PCI Patients at 48 Hours

Larry Husten, PHD

The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The […]

---

January 18th, 2012

Cangrelor and Alaska’s “Bridge to Nowhere”

Richard A. Lange, MD, MBA and L. David Hillis, MD

The Gravina Island Bridge (also known as The Bridge to Nowhere) was a proposed bridge to replace the ferry that currently connects Ketchikan, Alaska (population, 14,000) to the Ketchikan International Airport on Gravina Island (population, 50) at a projected cost of $398 million. The bridge was to have been nearly as long as the Golden Gate […]

---

January 17th, 2012

Cangrelor Proposed as Bridge to Surgery

Larry Husten, PHD

As a potent and reversible platelet inhibitor, cangrelor has been proposed for use in a bridging strategy for patients scheduled for surgery who are currently taking clopidogrel or another thienopyridine. To test this strategy, the BRIDGE investigators randomized 210 ACS or stent patients awaiting CABG and taking a thienopyridine to receive either cangrelor or placebo for at […]

---